FX Invest: Buy-side cautions on collateral

Vector illustration to show finances

More than half of buy-side traders would like to see eligible collateral extended to include equities, according to a survey produced jointly by technology vendor Algorthmics and consulting company Chromozome Consulting, in June.

The survey reveals that the buy-side would like to use the assets already in their portfolios as alternatives to eligible collateral asset types such as cash, government or corporate bonds. Of the respondents, 55% would like to use equities and 32% a share of funds. However, central clearing counterparties (CCP) are likely to require cash and high-quality bonds.

Asked how CCPs would affect bilateral collateral activity, 56% of respondents expect to need more collateral and 25% expect to see more counterparties collateralised.

A quarter of respondents are interested in optimising collateral. At a time when the costs of collateral funding could increase, this comes as no surprise: optimising collateral offers a way of minimising collateral cost through efficient reuse of collateral balances. For the same reasons, 22% cite measuring concentration limits on collateral positions as a priority.

Just over half of respondents (54%) say they make weekly rather than daily margin calls – despite 84% using vendor or outsourced collateral management systems. The vendor notes weekly margining will not meet the requirement for more frequent margining in central clearing.
The companies polled 80 buy-side institutions globally, including asset managers, hedge funds, pension funds and custodians.

Of them, 75% had between 100 and 500 CSA pairs, 75% had portfolios in excess of 500 live OTC positions and 72% use initial margin with 50% or more counterparties.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact customer services - www.fx-markets.com/static/contact-us, or view our subscription options here: https://subscriptions.fx-markets.com/subscribe

You are currently unable to copy this content. Please contact info@fx-markets.com to find out more.

You need to sign in to use this feature. If you don’t have a FX Markets account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: